Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 11/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.39 |
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559873 | 0.99 | PIM1 (0.42) | PIM1CHEK1ACHEFGFR3FGFR1 | |
| SCHEMBL1559826 | 0.86 | PIM1 (0.43) | PIM1CHEK1ACHEFGFR3FGFR1 | |
| SCHEMBL1561074 | 0.85 | PIM1 (0.39) | PIM1CHEK1ACHEFGFR3FGFR1 | |
| SCHEMBL1561286 | 0.82 | CHEK1 (0.56) | PIM1CHEK1ACHEFGFR3MAPT | |
| SCHEMBL12435884 | 0.82 | DYRK1A (0.38) | PIM1CHEK1ACHE | |
| SCHEMBL12435877 | 0.81 | DYRK1A (0.38) | PIM1CHEK1ACHEFGFR1 | |
| SCHEMBL1559896 | 0.78 | CHEK1 (0.46) | PIM1CHEK1ACHE | |
| SCHEMBL2214981 | 0.78 | PIM1 (0.37) | PIM1CHEK1ACHEFGFR3FGFR1 | |
| SCHEMBL1561134 | 0.75 | PAICS (0.40) | PIM1CHEK1ACHEFGFR3FGFR1 | |
| SCHEMBL1561400 | 0.70 | CHEK1 (0.60) | PIM1CHEK1ACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | PIM1 2969/4885CHEK1 786/4885ACHE 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.